-Bill Hicks
I'd argue that the surprise is rather on this: "In clinical trials, a single dose significantly outperformed standard treatments, offering hope to those who have found little relief elsewhere."
What's the difference between a derivate and a derivative?
(I'm not being facetious, I'd really rather like to know)
Inwards. Imagination, media, substances, meditation, solitude.
Interestingly, the paper only lists the following adverse effects: visual perceptual changes, nausea, and headache. Given that the patients in the double-blind study were those who suffer from moderate to severe Generalized Anxiety Disorder, I could imagine some significant anxiety in the 200 µg active group!
The paper only reports significant results at the 100 µg and 200 µg dose level, not less, which seems like another strike against psychedelic microdosing. The pharmaceutical industry would love to find a magic psychedelic drug which doesn't result in the psychedelic experience, but it seems like that experience is the key to their mental impact.
Yeah....
> Side effects were generally mild or moderate and included hallucinations, visual distortions, nausea, and headache. It's important to note, these were more prevalent using the highest dosage -- which we will not be using since it was found to be no more effective.
It's not the drugs that people with high anxiety need, it's people giving them attention and caring for them.
These experiments need a control where they just take the drug and they don't have medical staff around.
throwaway12pol•1h ago